ASX:BOT Botanix Pharmaceuticals (BOT) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Botanix Pharmaceuticals Stock (ASX:BOT) 30 days 90 days 365 days Advanced Chart Get BOT alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume1.63 million shsAverage VolumeN/AMarket CapitalizationA$912.82 millionP/E RatioN/ADividend Yield2.96%Price TargetN/AConsensus RatingN/A Company Overview Botanix Pharmaceuticals Limited engages in the research and development of dermatology and antimicrobial products in Australia. The company engages in development of novel treatments for common skin diseases and infections. Its product pipeline includes Sofpironium Bromide, a drug in development for the treatment of primary axillary hyperhidrosis that has completed Phase 3 clinical programs; BTX 1503, a transdermal gel formulation for the treatment of serious acne in adults and teenagers that has completed Phase II clinical trials; BTX 1801, which has completed Phase IIb clinical trials for the treatment of staphylococcus aureus and methicillin resistant staphylococcus aureus; BTX 1702 that is in Phase II clinical trials for the treatment of papulopustular rosacea; and BTX 1204A for the treatment of atopic dermatitis. Botanix Pharmaceuticals Limited was incorporated in 1984 and is based in Leederville, Australia. Read More Receive BOT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Botanix Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address BOT Stock News HeadlinesBOT - Botanix Pharmaceuticals Ltd Chart - MorningstarJuly 5 at 11:46 AM | morningstar.comMBotanix Pharmaceuticals to Host Webinar on Sofdra’s Market SuccessJuly 3 at 11:53 PM | tipranks.comEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal with Saudi Arabia to power its new AI empire 🤯 We’re talking about hundreds of thousands of chips, including their latest Grace Blackwell supercomputer.July 6 at 2:00 AM | Timothy Sykes (Ad)Botanix Pharmaceuticals Limited (BOT.AX)June 27, 2025 | uk.finance.yahoo.comDr Boreham’s Crucible: Can Sofdra become the ‘world’s most successful dermatology drug?’June 23, 2025 | msn.comBotanix Pharmaceuticals Issues New Warrants to Strengthen Market PositionJune 11, 2025 | tipranks.comHealth Check: Little Green Pharma’s European success is more than pot luckJune 10, 2025 | msn.comWhy Austal, Botanix, DroneShield, and NextDC shares are storming higher todayJune 9, 2025 | msn.comSee More Headlines BOT Stock Analysis - Frequently Asked Questions How were Botanix Pharmaceuticals' earnings last quarter? Botanix Pharmaceuticals Limited (ASX:BOT) issued its quarterly earnings data on Thursday, February, 28th. The company reported ($0.01) earnings per share (EPS) for the quarter. Botanix Pharmaceuticals had a negative net margin of 670.20% and a negative trailing twelve-month return on equity of 18.00%. What other stocks do shareholders of Botanix Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Botanix Pharmaceuticals investors own include Alphabet (GOOG), Meta Platforms (META), Arafura Rare Earths (ARU), Canopy Growth (CGC), Manning & Napier (MN), (STB.TO) (STB) and (YCB) (YCB). Company Calendar Last Earnings2/28/2019Today7/05/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolASX:BOT CIKN/A Webwww.botanixpharma.com Phone+61-8-94820580FaxN/AEmployees11Year FoundedN/AProfitability EPS (Trailing Twelve Months)A($0.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-A$13.87 million Net Margins-670.20% Pretax MarginN/A Return on Equity-18.00% Return on Assets-12.74% Debt Debt-to-Equity RatioN/A Current Ratio22.21 Quick Ratio1.26 Sales & Book Value Annual SalesA$2.07 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow1.50 Book ValueA$0.07 per share Price / BookN/AMiscellaneous Outstanding Shares1,810,000,000Free FloatN/AMarket CapA$912.82 million OptionableNot Optionable Beta1.71 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report This page (ASX:BOT) was last updated on 7/6/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored140% Yields From Stocks Like Tesla? Here's How (July 4th Special)Imagine getting a 140% dividend from your investments. Even better? It works with big names like Tesla, ...Investors Alley | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredThe day and month stocks are most likely to crash nextGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Botanix Pharmaceuticals Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Botanix Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.